Project Grant R21HD108460
Award Date
8/15/23
Completion Date
8/14/25
Dollars Obligated
$425K
Federal Agency
National Institute of Child Health and Human Development
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
This Project Grant award from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) provides $222,500.00 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) from May 15, 2025 to March 31, 2027. The funding supports the development of a modular system for mouse CRISPR genome and epigenome editing, including the creation of mouse lines that express CRISPR-interference/activation (CRISPR-I/A) and base/prime editing...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to improve the efficiency of CRISPR gene editing in human pluripotent stem cells. The goal is to develop a novel carbon nanotube array technology that can efficiently transfer nucleic acids and proteins into these cells to enhance CRISPR-based gene editing and homology-directed recombination. The $275,045 award to Advanced Gene...
This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $856,513 to optimize and integrate two computational and experimental approaches, CRISPRME and ABSOLVE-SEQ, into a comprehensive pipeline for assessing variant-associated off-target risks in genome editing therapeutics. The award aims to support Investigational New Drug (IND) applications by delivering standardized software modules, standard...
This federal Project Grant award for $378,123 from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports research to identify and test mechanisms that establish transcriptional regulatory potency in early embryos. The primary activities include using genomic methods like PRO-seq, DREG, and OMNI-ATAC to characterize transcriptionally active regulatory elements, DNA accessibility, and...
This Project Grant award, provided by the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351), aims to rapidly develop advanced mouse resource strains through the application of Prime Editing technology. The $265,500 award, granted on September 1, 2024, will fund research at the Jackson Laboratory to create a novel combinatorial system that can efficiently modify thousands of mouse genes by applying Prime Editing techniques. The key innovation is the...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $486,291 to Rutgers, The State University of New Jersey, Camden Division to develop nucleic acid nanoparticle (NANP) technology for efficiently delivering the CRISPR/Cas9 genome editing system into hematopoietic stem cells (HSCs). The goal is to enhance the targeting precision and efficacy of gene editing in HSCs to revolutionize the treatment of genetic blood...
This Project Grant award, valued at $107,458, was provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant aims to investigate the mechanisms of double strand break repair in fetal male germ cells, which are precursors to spermatogonial stem cells that supply sperm throughout a male's reproductive lifespan. The research, to be conducted at Duke...
This Project Grant award from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) provides $240,039 to Baylor College of Medicine to develop a novel mouse model for detecting genome editing events. The project aims to create a more sensitive reporter system based on the Cre-ERT2 recombinase system to improve detection of CRISPR/Cas9-mediated genome editing. This advanced animal model is expected to enable researchers to better evaluate the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $200,016 to The Regents of the University of California, San Francisco (UCSF) to develop a non-viral genome editing therapy for Artemis-deficient severe combined immunodeficiency (ART-SCID). The 5-year project aims to establish expertise in non-viral CRISPR/Cas9 editing of human hematopoietic stem cells, preclinical...
This Project Grant award, valued at $412,525.00 and issued by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports research focused on the molecular mechanisms that regulate ADAR target recognition and RNA editing. The award will fund an integrated research approach using human cell lines and the model organism Caenorhabditis elegans to investigate how ADAR binding to target RNAs is influenced by...